Abstract
The biological bases of cellular and organismal aging are thought to involve, among others, basic stress response mechanisms. In this field an increasing amount of evidence, in recent years, point towards an important role of endogenous retroelements. During evolution these mobile genetic elements interpreted the dual role of selfish genomic parasites and useful “boosters” of genomic evolution. Similarly, in living cell these elements have an important role in stress response and in generating neuronal plasticity, but studies on in vitro cell cultures and animal models show that their excessive activation or misregulation may lead to DNA damage and cell senescence, and can trigger both innate immunity and a pro-inflammatory response. Being cell senescence, somatic DNA damage and inflammation three supposed key processes in human aging, and observing that several intracellular mechanisms normally controlling the activation of retroelements show a tendency to fade at late ages, a possible role of endogenous retroelements in organismal senescence is taken in consideration. A better knowledge of the basic mechanisms linking stress response, activation of endogenous retroelements and age-related cell/tissue alterations could not only help us gain a better understanding of the basic mechanisms of aging, but will also allow the experimentation of new therapeutic targets for different age-related diseases.
Keywords: Aging, senescence, stress, retrotransposon, retroelement, antagonistic pleiotropy, hormesis, innate immunity, DNA damage, inflammation
Current Pharmaceutical Design
Title:Good, Bad, Mobile Elements: Genome’s Most Successful “Parasites” as Emerging Players in Cell and Organismal Aging
Volume: 19 Issue: 9
Author(s): Maurizio Cardelli and Francesca Marchegiani
Affiliation:
Keywords: Aging, senescence, stress, retrotransposon, retroelement, antagonistic pleiotropy, hormesis, innate immunity, DNA damage, inflammation
Abstract: The biological bases of cellular and organismal aging are thought to involve, among others, basic stress response mechanisms. In this field an increasing amount of evidence, in recent years, point towards an important role of endogenous retroelements. During evolution these mobile genetic elements interpreted the dual role of selfish genomic parasites and useful “boosters” of genomic evolution. Similarly, in living cell these elements have an important role in stress response and in generating neuronal plasticity, but studies on in vitro cell cultures and animal models show that their excessive activation or misregulation may lead to DNA damage and cell senescence, and can trigger both innate immunity and a pro-inflammatory response. Being cell senescence, somatic DNA damage and inflammation three supposed key processes in human aging, and observing that several intracellular mechanisms normally controlling the activation of retroelements show a tendency to fade at late ages, a possible role of endogenous retroelements in organismal senescence is taken in consideration. A better knowledge of the basic mechanisms linking stress response, activation of endogenous retroelements and age-related cell/tissue alterations could not only help us gain a better understanding of the basic mechanisms of aging, but will also allow the experimentation of new therapeutic targets for different age-related diseases.
Export Options
About this article
Cite this article as:
Cardelli Maurizio and Marchegiani Francesca, Good, Bad, Mobile Elements: Genome’s Most Successful “Parasites” as Emerging Players in Cell and Organismal Aging, Current Pharmaceutical Design 2013; 19 (9) . https://dx.doi.org/10.2174/1381612811319090021
DOI https://dx.doi.org/10.2174/1381612811319090021 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clostridial Neurotoxins: Mode of Substrate Recognition and Novel Therapy Development
Current Protein & Peptide Science Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets Application of Proteomics to the Discovery of Cancer Biomarkers
Current Cancer Therapy Reviews Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis
Current Signal Transduction Therapy Iron Chelators as Potential Therapeutic Agents for Parkinsons Disease
Current Bioactive Compounds Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo
Current Drug Metabolism Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review
Current Alzheimer Research Emerging Technologies for Fertility Preservation in Female Patients
Current Women`s Health Reviews Nanotechnology for Alzheimer Disease
Current Alzheimer Research Oxidative Stress and NAD+ in Ischemic Brain Injury: Current Advances and Future Perspectives
Current Medicinal Chemistry Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Immunophilins: Structures, Mechanisms and Ligands
Current Molecular Pharmacology Beneficial Effects of Lysosome-Modulating and Other Pharmacological and Nanocarrier Agents on Amyloid-beta-treated Cells
Current Pharmaceutical Biotechnology